| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.26▲ | 2.25▲ | 2.25▲ | 2.28▼ | 2.60▼ |
| MA10 | 2.25▲ | 2.27▲ | 2.29▼ | 2.42▼ | 2.50▼ |
| MA20 | 2.31▼ | 2.32▼ | 2.30▼ | 2.60▼ | 2.22▲ |
| MA50 | 2.34▼ | 2.34▼ | 2.42▼ | 2.52▼ | 2.01▲ |
| MA100 | 2.39▼ | 2.52▼ | 2.58▼ | 2.21▲ | 2.68▼ |
| MA200 | 2.56▼ | 2.69▼ | 2.66▼ | 2.06▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.004▼ | -0.004▼ | 0.002▲ | -0.062▼ | 0.014▲ |
| RSI | 45.462▼ | 46.370▼ | 45.813▼ | 40.036▼ | 50.441▲ |
| STOCH | 43.921 | 25.725 | 23.479 | 9.518▼ | 54.588 |
| WILL %R | -56.522 | -56.522 | -66.667 | -85.000▼ | -69.925 |
| CCI | -8.028 | -38.928 | -48.474 | -96.581 | -42.521 |
|
Friday, August 08, 2025 06:56 AM
Insiders who bought Immix Biopharma, Inc. ( NASDAQ:IMMX ) in the last 12 months may probably not pay attention to ...
|
|
Wednesday, August 06, 2025 09:42 AM
Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – Company plans to partner-out Other Serious Disease programs – – On track for first Biologics License Application (BLA) ...
|
|
Sunday, July 27, 2025 05:00 PM
IMAX (NYSE:IMAX – Free Report) had its price objective raised by Wells Fargo & Company from $30.00 to $34.00 in a research report released on Friday morning, Benzinga reports.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 2.20 | 2.3094 | 2.19 | 2.27 | 119,548 |
| 14/08/25 | 2.30 | 2.3682 | 2.15 | 2.19 | 135,440 |
| 13/08/25 | 2.30 | 2.50 | 2.29 | 2.33 | 463,150 |
| 12/08/25 | 2.32 | 2.3301 | 2.2427 | 2.30 | 95,050 |
| 11/08/25 | 2.39 | 2.49 | 2.25 | 2.32 | 193,220 |
| 08/08/25 | 2.40 | 2.4667 | 2.35 | 2.39 | 118,010 |
| 07/08/25 | 2.62 | 2.67 | 2.35 | 2.39 | 366,895 |
| 06/08/25 | 2.95 | 2.95 | 2.53 | 2.595 | 519,055 |
| 05/08/25 | 2.58 | 2.92 | 2.57 | 2.85 | 723,314 |
| 04/08/25 | 2.71 | 2.775 | 2.50 | 2.54 | 252,685 |
|
|
||||
|
|
||||
|
|